SPOTLIGHT: Genzyme wins Myozyme OK

Genzyme has won FDA approval to market Myozyme for Pompe disease, a regulatory win that could open the way to a billion dollars in annual revenue. Genzyme spent eight years and $500 million developing the drug for the rare condition. Report

Suggested Articles

In this week's EuroBiotech Report, GSK, Immatics strike cell therapy deal, Vifor buys priority review voucher and PharmaMar gets PDUFA date.

In our EuroBiotech roundup this week, U.K. creates life science zones, Genmab to ramp up R&D spending and Pfizer backs cancer biotech. 

Spruce Biosciences raised $88 million from the likes of Abingworth and Omega Funds to take the drug to the next level: a late-stage study in adults.